AU2009204998B2 - Purification of non-glycosylated proteins - Google Patents

Purification of non-glycosylated proteins Download PDF

Info

Publication number
AU2009204998B2
AU2009204998B2 AU2009204998A AU2009204998A AU2009204998B2 AU 2009204998 B2 AU2009204998 B2 AU 2009204998B2 AU 2009204998 A AU2009204998 A AU 2009204998A AU 2009204998 A AU2009204998 A AU 2009204998A AU 2009204998 B2 AU2009204998 B2 AU 2009204998B2
Authority
AU
Australia
Prior art keywords
chromatography
heterologous polypeptide
steps
chromatography step
hydrophobic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009204998A
Other languages
English (en)
Other versions
AU2009204998A1 (en
Inventor
Roberto Falkenstein
Nicole Fuehrler
Claudia Giessel
Sybille Greithanner
Adelbert Grossmann
Frederike Hesse
Brigitte Kraemer
Marc Pompiati
Andreas Schaubmar
Birgit Weydanz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2009204998A1 publication Critical patent/AU2009204998A1/en
Application granted granted Critical
Publication of AU2009204998B2 publication Critical patent/AU2009204998B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2009204998A 2008-01-18 2009-01-15 Purification of non-glycosylated proteins Ceased AU2009204998B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08000884.0 2008-01-18
EP08000884 2008-01-18
PCT/EP2009/000192 WO2009090056A2 (en) 2008-01-18 2009-01-15 Purification of not-glycosylated polypeptides

Publications (2)

Publication Number Publication Date
AU2009204998A1 AU2009204998A1 (en) 2009-07-23
AU2009204998B2 true AU2009204998B2 (en) 2014-03-27

Family

ID=39810157

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009204998A Ceased AU2009204998B2 (en) 2008-01-18 2009-01-15 Purification of non-glycosylated proteins

Country Status (9)

Country Link
US (3) US20110034672A1 (cg-RX-API-DMAC7.html)
EP (1) EP2245044A2 (cg-RX-API-DMAC7.html)
JP (2) JP5944101B2 (cg-RX-API-DMAC7.html)
KR (1) KR20100103595A (cg-RX-API-DMAC7.html)
CN (2) CN101918430A (cg-RX-API-DMAC7.html)
AU (1) AU2009204998B2 (cg-RX-API-DMAC7.html)
CA (1) CA2711375C (cg-RX-API-DMAC7.html)
IL (1) IL206158A (cg-RX-API-DMAC7.html)
WO (1) WO2009090056A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101918430A (zh) * 2008-01-18 2010-12-15 弗·哈夫曼-拉罗切有限公司 非糖基化蛋白质的纯化
DE102009032179A1 (de) * 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
CN102219848B (zh) * 2011-05-25 2014-01-22 浙江海正药业股份有限公司 重组人干扰素β-1a的纯化方法
US20140154233A1 (en) 2012-12-05 2014-06-05 Csl Limited Method of purifying therapeutic proteins
US10188965B2 (en) 2012-12-05 2019-01-29 Csl Behring Gmbh Hydrophobic charge induction chromatographic depletion of a protein from a solution
CN104710527B (zh) * 2015-02-28 2018-08-24 苏州金盟生物技术有限公司 一种生物制品的内毒素去除方法
HUE049756T2 (hu) * 2015-11-09 2020-10-28 Biological E Ltd Ipari méretekben is alkalmazható eljárás biológiailag aktív, rekombináns hordozófehérjék kinyerésére
TW202128264A (zh) 2019-09-25 2021-08-01 瑞士商赫孚孟拉羅股份公司 使用經預測之溶離緩衝鹽濃度的陽離子層析法
KR20220145361A (ko) * 2020-02-24 2022-10-28 노파르티스 아게 재조합적으로 생성된 폴리펩타이드의 정제
KR20230125179A (ko) * 2020-12-23 2023-08-29 재즈 파마슈티칼즈 아일랜드 리미티드 전하-차폐 융합 단백질의 정제 방법
CN113480632B (zh) * 2021-07-30 2023-02-03 宁波人健药业集团股份有限公司 一种在CHO细胞中表达的重组蛋白rhCG纯化工艺
TW202403043A (zh) * 2022-03-18 2024-01-16 美商健臻公司 重組人類酸性鞘磷脂酶醫藥組合物及方法
CN117024561B (zh) * 2023-10-10 2024-02-20 哈药集团生物工程有限公司 一种聚乙二醇修饰干扰素的纯化方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710027A (en) * 1993-05-26 1998-01-20 Boehringer Ingelheim International Gmbh Process and vector for expressing alpha-interferon in E. coli
WO2005094960A1 (en) * 2004-04-02 2005-10-13 Ge Healthcare Bio-Sciences Ab A method for chromatographic purification
US20050266465A1 (en) * 2004-05-19 2005-12-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
WO2007041713A1 (en) * 2005-10-04 2007-04-12 Zymogenetics, Inc. Production and purification of il-29

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH651308A5 (de) * 1980-07-01 1985-09-13 Hoffmann La Roche Interferone und deren herstellung.
US5696238A (en) * 1991-08-20 1997-12-09 Chiron Corporation Purified GP120 composition retaining natural conformation
DE4329756A1 (de) * 1993-09-03 1995-03-09 Boehringer Ingelheim Int Verfahren zur Herstellung und Reinigung von alpha-Interferon
EP1104809A1 (en) * 1994-04-09 2001-06-06 F. Hoffmann-La Roche Ag Process for producing alpha-interferon
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
KR100443890B1 (ko) 2001-04-11 2004-08-09 한미약품 주식회사 재조합 대장균으로부터 인간 성장 호르몬의 정제 방법
CN1233816C (zh) * 2002-04-16 2005-12-28 海南海梁生物高科技有限公司 酵母重组株及IFNα-la干扰素的纯化方法
SI1501369T1 (sl) * 2002-04-26 2015-10-30 Genentech, Inc. Neafinitetno čiščenje proteinov
SI1656455T1 (sl) * 2003-08-13 2012-12-31 Sandoz Ag Postopek za čiščenje rekombinantnih polipeptidov
ES2285543T3 (es) 2003-11-05 2007-11-16 Ares Trading S.A. Procedimiento para la purificacion de la proteina de union a il-18.
ATE446314T1 (de) 2003-12-22 2009-11-15 Ares Trading Sa Methode zur reinigung von fsh
CA2602947A1 (en) 2005-03-24 2006-09-28 Straumann Holding Ag Method for protein purification comprising heat incubation in acetic acidic solution
WO2007016250A1 (en) 2005-07-28 2007-02-08 Genvec, Inc. Method of purifying protein
CN1916024A (zh) * 2005-08-17 2007-02-21 海南国栋药物研究所有限公司 高比活人α-2b干扰素突变体序列、酵母表达质粒的构建及菌株筛选和纯化方法
EP1963367A4 (en) 2005-12-06 2009-05-13 Amgen Inc POLISHING STEPS IN MULTI-STAGE PROTEIN PURIFICATION TREATMENTS
CN101918430A (zh) * 2008-01-18 2010-12-15 弗·哈夫曼-拉罗切有限公司 非糖基化蛋白质的纯化
CN103864915B (zh) * 2012-12-07 2016-06-08 天津未名生物医药有限公司 纯化重组人干扰素α2b的方法和试剂盒
CN104356223B (zh) * 2014-11-26 2017-11-10 安徽安科生物工程(集团)股份有限公司 高纯度重组人干扰素α2b的制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710027A (en) * 1993-05-26 1998-01-20 Boehringer Ingelheim International Gmbh Process and vector for expressing alpha-interferon in E. coli
WO2005094960A1 (en) * 2004-04-02 2005-10-13 Ge Healthcare Bio-Sciences Ab A method for chromatographic purification
US20050266465A1 (en) * 2004-05-19 2005-12-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
WO2007041713A1 (en) * 2005-10-04 2007-04-12 Zymogenetics, Inc. Production and purification of il-29

Also Published As

Publication number Publication date
KR20100103595A (ko) 2010-09-27
US9481706B2 (en) 2016-11-01
JP2011509963A (ja) 2011-03-31
CA2711375C (en) 2019-04-16
JP5944101B2 (ja) 2016-07-05
IL206158A0 (en) 2010-12-30
US20110034672A1 (en) 2011-02-10
US20130190478A1 (en) 2013-07-25
CA2711375A1 (en) 2009-07-23
WO2009090056A3 (en) 2010-01-21
CN107033233A (zh) 2017-08-11
CN101918430A (zh) 2010-12-15
WO2009090056A2 (en) 2009-07-23
AU2009204998A1 (en) 2009-07-23
US20140220633A1 (en) 2014-08-07
JP2014210797A (ja) 2014-11-13
EP2245044A2 (en) 2010-11-03
IL206158A (en) 2016-09-29

Similar Documents

Publication Publication Date Title
CA2711375C (en) Purification of not-glycosylated polypeptides
EP2552948B1 (en) Process for the purification of growth factor protein g-csf
KR101593766B1 (ko) 혼합식 크로마토그래피에 의한 최적화된 항체 포획 방법
CN101889023A (zh) Peg化的多肽的纯化
US11332514B2 (en) Cation and anion exchange chromatography method
JP5635682B2 (ja) 疎水性相互作用クロマトグラフィー法
AU2013203253B2 (en) Process for the purification of a growth factor protein
HK1181458A (en) Hydrophobic interaction chromatography method
HK1193617A (en) Cation and anion exchange chromatography method
HK1193617B (en) Cation and anion exchange chromatography method

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ WEYDANZ, BIRGIT; POMPIATI, MARC; SCHAUBMAR, ANDREAS; GIESSEL, CLAUDIA; GROSSMANN, ADELBERT; KRAEMER, BRIGITTE; FALKENSTEIN, ROBERTO; FUEHRLER, NICOLE; HESSE, FREDERIKE AND GREITHANNER, SYBILLE

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired